Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01482962 · ClinicalTrials.gov registry record · Phase 3
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
A Phase 3 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 271
- Enrollment target
NCT01482962 is a Phase 3 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 271 participants.
The verdict
NCT01482962, a Phase 3 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 271 participants
- Enrollment target
Study Summary
This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexate or gemcitabine or romidepsin, in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL). Note: romidepsin was not used as a single-agent comparator outside the United States of America (USA) as supply was not available.
Interventions
- DRUG Gemcitabine
- DRUG Alisertib
- DRUG Pralatrexate
- DRUG Romidepsin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 271 participants |
| Start Date | 2012-06-11 |
| Est. Completion | 2017-12-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01482962
The ClinicalTrials.gov registry entry for NCT01482962 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 271 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Gemcitabine is the first listed.
NCT01482962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01482962 about?
NCT01482962 is a clinical study titled "Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma". This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexate or gemcitabine or romidepsin, in participants with relapsed or refractory peripheral T-cell lympho...
What is the current status of trial NCT01482962?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 271 participants. The study started on 2012-06-11. Estimated completion is 2017-12-18.
What interventions are being tested in trial NCT01482962?
The interventions under investigation include: Gemcitabine (DRUG), Alisertib (DRUG), Pralatrexate (DRUG), Romidepsin (DRUG).
Who is sponsoring clinical trial NCT01482962?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.